Efficacy and safety of irbesartan/HCTZ in severe hypertension according to
cardiometabolic factors.
Author(s): Franklin SS, Neutel JM.
Affiliation(s): Department of Medicine, University of California, Irvine, CA, USA.
ssfranklinmd@earthlink.net
Publication date & source: 2010, J Clin Hypertens (Greenwich). , 12(7):487-94
This post hoc analysis of a 7-week, randomized, double-blind trial evaluated the
efficacy and safety of initial irbesartan/hydrochlorothiazide treatment in 468
patients with severe, uncontrolled, hypertension (diastolic blood pressure [DBP]
> or =100 mm Hg) at high cardiovascular risk. Systolic blood pressure (SBP)/DBP
reductions ranged from 28.0 to 42.9/22.9 to 27.2 mm Hg in patients with obesity,
diabetes, baseline SBP > or =180 mm Hg, and in the elderly. Blood pressure
control to <140/90 mm Hg in the age and obesity subgroups ranged from 32.1% to
39.2% while control to <130/80 mm Hg in patients with diabetes was 11.5%. After 1
week of therapy, 72.5% of patients no longer had SBP > or =180 mm Hg; by 7 weeks,
51.3% had SBP 140 to 159 mm Hg and 26.5% had SBP <140 mm Hg. Treatment was well
tolerated regardless of the subgroup. No excess of prespecified events was noted.
Thus, initial treatment with irbesartan/hydrochlorothiazide was rapidly effective
in high-risk, difficult-to-treat, severely hypertensive patients.
|